1H and 31P magnetic resonance spectroscopy reveals potential pathogenic and biomarker metabolite alterations in Lafora disease

Abstract Lafora disease is a fatal teenage-onset progressive myoclonus epilepsy and neurodegenerative disease associated with polyglucosan bodies. Polyglucosans are long-branched and as a result precipitation- and aggregation-prone glycogen. In mouse models, downregulation of glycogen synthase, the enzyme that elongates glycogen branches, prevents polyglucosan formation and rescues Lafora disease. Mouse work, however, has not yet revealed the mechanisms of polyglucosan generation, and few in vivo human studies have been performed. Here, non-invasive in vivo magnetic resonance spectroscopy (1H and 31P) was applied to test scan feasibility and assess neurotransmitter balance and energy metabolism in Lafora disease towards a better understanding of pathogenesis. Macromolecule-suppressed gamma-aminobutyric acid (GABA)-edited 1H magnetic resonance spectroscopy and 31P magnetic resonance spectroscopy at 3 and 7 tesla, respectively, were performed in 4 Lafora disease patients and a total of 21 healthy controls (12 for the 1H magnetic resonance spectroscopy and 9 for the 31PMRS). Spectra were processed using in-house software and fit to extract metabolite concentrations. From the 1H spectra, we found 33% lower GABA concentrations (P = 0.013), 34% higher glutamate + glutamine concentrations (P = 0.011) and 24% lower N-acetylaspartate concentrations (P = 0.0043) in Lafora disease patients compared with controls. From the 31P spectra, we found 34% higher phosphoethanolamine concentrations (P = 0.016), 23% lower nicotinamide adenine dinucleotide concentrations (P = 0.003), 50% higher uridine diphosphate glucose concentrations (P = 0.004) and 225% higher glucose 6-phosphate concentrations in Lafora disease patients versus controls (P = 0.004). Uridine diphosphate glucose is the substrate of glycogen synthase, and glucose 6-phosphate is its extremely potent allosteric activator. The observed elevated uridine diphosphate glucose and glucose 6-phosphate levels are expected to hyperactivate glycogen synthase and may underlie the generation of polyglucosans in Lafora disease. The increased glutamate + glutamine and reduced GABA indicate altered neurotransmission and energy metabolism, which may contribute to the disease’s intractable epilepsy. These results suggest a possible basis of polyglucosan formation and potential contributions to the epilepsy of Lafora disease. If confirmed in larger human and animal model studies, measurements of the dysregulated metabolites by magnetic resonance spectroscopy could be developed into non-invasive biomarkers for clinical trials.

[1]  Chi Wang,et al.  In situ microwave fixation provides an instantaneous snapshot of the brain metabolome , 2023, Cell reports methods.

[2]  M. Garcia-Gimeno,et al.  Deciphering the Polyglucosan Accumulation Present in Lafora Disease Using an Astrocytic Cellular Model , 2023, International journal of molecular sciences.

[3]  U. Mayor,et al.  P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease , 2023, Neurobiology of Disease.

[4]  Peixiang Wang,et al.  Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy , 2022, Disease models & mechanisms.

[5]  F. Yu,et al.  ATP line splitting in association with reduced intracellular magnesium and pH: a brain 31P MR spectroscopic imaging (MRSI) study of pediatric patients with myelin oligodendrocyte glycoprotein antibody‐associated disorders (MOGADs) , 2022, NMR in biomedicine.

[6]  C. Majós,et al.  High Myoinositol on Proton MR Spectroscopy Could Be a Potential Signature of Papillary Tumors of the Pineal Region—Case Report of Two Patients , 2022, Brain sciences.

[7]  L. Ruhm,et al.  Measurement of glucose metabolism in the occipital lobe and frontal cortex after oral administration of [1-13C]glucose at 9.4 T , 2022, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Kimberly L. Chan,et al.  Improved prospective frequency correction for macromolecule‐suppressed GABA editing with metabolite cycling at 3T , 2021, Magnetic resonance in medicine.

[9]  E. Gumusgoz,et al.  Lafora disease: Current biology and therapeutic approaches. , 2021, Revue neurologique.

[10]  K. Holton,et al.  Brain concentrations of glutamate and GABA in human epilepsy: A review , 2021, Seizure.

[11]  E. Porges,et al.  The trajectory of cortical GABA across the lifespan, an individual participant data meta-analysis of edited MRS studies , 2021, eLife.

[12]  A. Sherry,et al.  31P‐MRS of the healthy human brain at 7 T detects multiple hexose derivatives of uridine diphosphate glucose , 2021, NMR in biomedicine.

[13]  F. Nitschke,et al.  Targeting Gys1 with AAV‐SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models , 2021, Neurotherapeutics.

[14]  C. Muñoz-Ballester,et al.  Endocytosis of the glutamate transporter 1 is regulated by laforin and malin: Implications in Lafora disease , 2020, Glia.

[15]  Wolfgang Bogner,et al.  Contribution of macromolecules to brain 1H MR spectra: Experts' consensus recommendations , 2020, NMR in biomedicine.

[16]  Valerie J. Sydnor,et al.  A quantitative meta-analysis of brain glutamate metabolites in aging , 2020, Neurobiology of Aging.

[17]  N. Zölch,et al.  Brain proton magnetic resonance spectroscopy findings in a Beagle dog with genetically confirmed Lafora disease , 2020, Journal of veterinary internal medicine.

[18]  M. Hottiger,et al.  Regulation of Glucose Metabolism by NAD+ and ADP-Ribosylation , 2019, Cells.

[19]  Matthew S. Gentry,et al.  Targeting pathogenic Lafora bodies in Lafora disease using an antibody-enzyme fusion , 2019, bioRxiv.

[20]  David White,et al.  Neurochemical changes in the aging brain: A systematic review , 2019, Neuroscience & Biobehavioral Reviews.

[21]  Heinrich Lanfermann,et al.  Effects of Aging on the Human Brain: A Proton and Phosphorus MR Spectroscopy Study at 3T , 2018, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[22]  Kimberly L. Chan,et al.  Simultaneous detection of glutathione and lactate using spectral editing at 3 T , 2017, NMR in biomedicine.

[23]  P. Bovolenta,et al.  Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease , 2017, EMBO molecular medicine.

[24]  Peter Jezzard,et al.  Advanced processing and simulation of MRS data using the FID appliance (FID‐A)—An open source, MATLAB‐based toolkit , 2017, Magnetic resonance in medicine.

[25]  Kawaguchi Hirokazu,et al.  Detection of glucose in the human brain with 1H MRS at 7 Tesla , 2016, Magnetic resonance in medicine.

[26]  C. Muñoz-Ballester,et al.  Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease. , 2016, Biochimica et biophysica acta.

[27]  Craig R Malloy,et al.  31P‐MRS of healthy human brain: ATP synthesis, metabolite concentrations, pH, and T1 relaxation times , 2015, NMR in biomedicine.

[28]  Peter Jezzard,et al.  Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain , 2015, Magnetic resonance in medicine.

[29]  R. Edden,et al.  Gannet: A batch‐processing tool for the quantitative analysis of gamma‐aminobutyric acid–edited MR spectroscopy spectra , 2014, Journal of magnetic resonance imaging : JMRI.

[30]  E. Hattingen,et al.  Frontal and thalamic changes of GABA concentration indicate dysfunction of thalamofrontal networks in juvenile myoclonic epilepsy , 2014, Epilepsia.

[31]  J. Delgado-García,et al.  Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. , 2014, Human molecular genetics.

[32]  J. Rothwell,et al.  The role of the cerebellum in the pathogenesis of cortical myoclonus , 2014, Movement disorders : official journal of the Movement Disorder Society.

[33]  R. Agís-Balboa,et al.  Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease , 2014, Molecular Brain.

[34]  P. Stanwell,et al.  Glutamate and glutamine: a review of in vivo MRS in the human brain , 2013, NMR in biomedicine.

[35]  C. Rae A Guide to the Metabolic Pathways and Function of Metabolites Observed in Human Brain 1H Magnetic Resonance Spectra , 2013, Neurochemical Research.

[36]  C. Ackerley,et al.  Inhibiting glycogen synthesis prevents lafora disease in a mouse model , 2013, Annals of neurology.

[37]  S. Shankar,et al.  Neuronatin-mediated Aberrant Calcium Signaling and Endoplasmic Reticulum Stress Underlie Neuropathology in Lafora Disease* , 2013, The Journal of Biological Chemistry.

[38]  A. Depaoli-Roach,et al.  Glycogen and its metabolism: some new developments and old themes. , 2012, The Biochemical journal.

[39]  J. Delgado-García,et al.  Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease , 2011, EMBO molecular medicine.

[40]  Gülin Öz,et al.  Short‐echo, single‐shot, full‐intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: Validation in the cerebellum and brainstem , 2011, Magnetic resonance in medicine.

[41]  P. Roach,et al.  Genetic Depletion of the Malin E3 Ubiquitin Ligase in Mice Leads to Lafora Bodies and the Accumulation of Insoluble Laforin* , 2010, The Journal of Biological Chemistry.

[42]  Federico Zara,et al.  Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease , 2010, Epilepsy Research.

[43]  C. Ackerley,et al.  22‐YEAR‐OLD GIRL WITH STATUS EPILEPTICUS AND PROGRESSIVE NEUROLOGICAL SYMPTOMS , 2009, Brain pathology.

[44]  A. Sakamoto,et al.  Magnetic resonance spectroscopy reveals an epileptic network in juvenile myoclonic epilepsy , 2009, Epilepsia.

[45]  A. Depaoli-Roach,et al.  Abnormal Metabolism of Glycogen Phosphate as a Cause for Lafora Disease* , 2008, Journal of Biological Chemistry.

[46]  A. Pichiecchio,et al.  Lafora disease: spectroscopy study correlated with neuropsychological findings. , 2008, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[47]  A. Delgado-Escueta,et al.  Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo , 2007, Proceedings of the National Academy of Sciences.

[48]  C. Worby,et al.  Laforin, a Dual Specificity Phosphatase That Dephosphorylates Complex Carbohydrates* , 2006, Journal of Biological Chemistry.

[49]  Jong-Min Lee,et al.  Structural Brain Abnormalities in Juvenile Myoclonic Epilepsy Patients: Volumetry and Voxel-Based Morphometry , 2006, Korean journal of radiology.

[50]  J. Serratosa,et al.  MRI Volumetry and Proton MR Spectroscopy of the Brain in Lafora Disease , 2006, Epilepsia.

[51]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[52]  C. Worby,et al.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Avanzini,et al.  Sensorimotor cortex excitability in Unverricht–Lundborg disease and Lafora body disease , 2004, Neurology.

[54]  I Savic,et al.  MRS shows syndrome differentiated metabolite changes in human-generalized epilepsies , 2004, NeuroImage.

[55]  G Avanzini,et al.  Movement-activated myoclonus in genetically defined progressive myoclonic epilepsies: EEG–EMG relationship estimated using autoregressive models , 2003, Clinical Neurophysiology.

[56]  John S Duncan,et al.  A Proton Magnetic Resonance Spectroscopy Study of Metabolites in the Occipital Lobes in Epilepsy , 2003, Epilepsia.

[57]  D L Rothman,et al.  Spectroscopic Assessment of Alterations in Macromolecule and Small-Molecule Metabolites in Human Brain After Stroke , 2001, Stroke.

[58]  U Klose,et al.  Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. , 2001, Brain : a journal of neurology.

[59]  S. A. Mayer,et al.  Access www.neurology.org now for full-text articles , 2001, Neurology.

[60]  V. Govindaraju,et al.  Proton NMR chemical shifts and coupling constants for brain metabolites , 2000, NMR in biomedicine.

[61]  R Gruetter,et al.  Extracellular–Intracellular Distribution of Glucose and Lactate in the Rat Brain Assessed Noninvasively by Diffusion-Weighted 1H Nuclear Magnetic Resonance Spectroscopy In Vivo , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[62]  I Savic,et al.  MR Spectroscopy Shows Reduced Frontal Lobe Concentrations of N‐Acetyl Aspartate in Patients with Juvenile Myoclonic Epilepsy , 2000, Epilepsia.

[63]  Z. Meiner,et al.  Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329 Ser mutation in the glycogen‐branching enzyme gene , 1998, Annals of neurology.

[64]  R. Shulman,et al.  31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. , 1992, The Journal of clinical investigation.

[65]  M. Elzinga,et al.  Nucleotide sequence of the fadA gene. Primary structure of 3-ketoacyl-coenzyme A thiolase from Escherichia coli and the structural organization of the fadAB operon. , 1990, The Journal of biological chemistry.

[66]  Gonzalo R. Lafora,et al.  Beitrag zur Histopathologie der myoklonischen Epilepsie , 1911 .

[67]  C. Tassinari,et al.  [Lafora disease (author's transl)]. , 1978, Revue d'electroencephalographie et de neurophysiologie clinique.